Role of transgelin-2 in diabetes-associated pancreatic ductal adenocarcinoma
Metrics: PDF 818 views | HTML 1515 views | ?
Yan Sun1,*, Weiwei He2,*, Man Luo1, Yuhong Zhou3, Guilin Chang1, Weiying Ren1, Kefen Wu1, Xi Li1, Jiping Shen1, Xiaoping Zhao4 and Yu Hu1
1Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Thoracic Surgery, Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
3Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
*These authors have contributed equally to this work
Xiaoping Zhao, email: firstname.lastname@example.org
Yu Hu, email: email@example.com
Keywords: transgelin-2, SREBP, PDAC, diabetes, insulin
Received: June 29, 2016 Accepted: March 29, 2017 Published: April 29, 2017
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis. Diabetes is a significant risk factor for PDAC and >50% of PDAC patients have concomitant diabetes. How diabetes influences the initiation and progression of PDAC remains elusive. Here, we show that transgelin-2 is dominantly expressed in PDAC tissues compared with adjacent normal tissues. The high level of transgelin-2 indicates poor survival of patients with PDAC. Remarkably, transgelin-2 expression is correlated with diabetic status. Hyperinsulinemia is frequently observed in type 2 diabetes. Our results indicate that upregulation of transgelin-2 is induced by insulin via sterol regulatory element-binding protein (SREBP)-1-mediated transcription in PDAC cells. Transgelin-2 is a novel target of SREBP-1. Our data support a novel mechanism in diabetes-associated PDAC by which transgelin-2 mediates proliferation of PDAC cells upon insulin stimulation. The insulin/SREBP-1/transgelin-2 network should be further explored as a diagnostic marker or a novel therapeutic target for diabetes-associated PDAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.